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ABSTRACT: In vitro culture of Plasmodium vivax liver stages underlies key understandings of the fundamental biology of this
parasite, particularly the latent, hyponozoite stage, toward drug and vaccine development. Here, we report systematic production
of Plasmodium vivax sporozoites in colonized Anopheles darlingi mosquitoes in the Peruvian Amazon. Human subject-derived
P. vivax-infected blood was fed to Anopheles darlingi females using standard membrane feedings assays. Optimizing A. darlingi
infection and sporozoite production included replacement of infected patient donor serum with naiv̈e donor serum, comparing
anticoagulants in processing blood samples, and addition of penicillin−streptomycin and ATP to infectious blood meals.
Replacement of donor serum by naiv̈e serum in the P. vivax donor blood increased oocysts in the mosquito midgut, and heparin,
as anticoagulant, was associated with the highest sporozoite yields. Maintaining blood-fed mosquitoes on penicillin−streptomycin
in sugar signiﬁcantly extended mosquito survival which enabled greater sporozoite yield. In this study, we have shown that a
robust P. vivax sporozoite production is feasible in a malaria-endemic setting where infected subjects and a stable A. darlingi
colony are brought together, with optimized laboratory conditions.
KEYWORDS: Plasmodium vivax, Anopheles darlingi, Peruvian Amazon, membrane feeding assays, sporozoite
Malaria remains a global health problem despiteenormous, worldwide control eﬀorts. Of the Plasmodium
parasites aﬀecting humans, Plasmodium vivax has the largest
geographic range with the highest risk in tropical endemic
regions. In addition to aﬀecting residents of endemic areas,
travelers and military personnel visiting P. vivax-endemic areas
are at risk for acute and relapsing malaria due to this parasite.
Developing new drug- and vaccine-based primary prevention
interventions will rely on better understandings of the biology
of P. vivax−hepatocyte interactions. Such work requires access
to large numbers of P. vivax sporozoites, which hitherto have
been diﬃcult to obtain.
The current inability to study the biology of the hepatic
stages of P. vivax, particularly (but not exclusively) hypnozoites,
the quiescent liver forms, complicates the goal of malaria
elimination. With no current diagnostic method to detect these
forms and relapse episodes sustaining malaria transmission, a
radical cure seems diﬃcult to achieve.1 In addition, there is a
high proportion of blood stage infections that are diﬃcult to
detect because asymptomatic carriers and/or submicroscopic
infections are undetectable by standard diagnostic methods,2
especially given that most relapses (reactivation of hypnozoites)
are asymptomatic.3
One challenge for the study of P. vivax biology is that
continuous in vitro culture of P. vivax remains unfeasible,4
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making it necessary to use primate models, for example,
Plasmodium cynomolgi-infected rhesus macaques,5,6 as source
material to approximate P. vivax biology. Although P. vivax
hepatocyte development can be studied in in vitro cell culture7
as well as with primary hepatocyte models,8,9 such as the
microliver platform,6,10 these are not widely used because
P. vivax sporozoites are diﬃcult to obtain. Vaccines based on
attenuated sporozoites against Plasmodium falciparum are in
diﬀerent stages of clinical trials,11,12 whereas this type of vaccine
has been underexplored for P. vivax, in part due to
unavailability of P. vivax sporozoites.
To continuously produce P. vivax sporozoites, an unin-
terrupted supply of mosquitoes as well as access to infectious
gametocytes are required. Anopheles darlingi, the main malaria
vector in Amazonia, has been recently established as a
stenogamous colony (free-mating).13,14 Susceptibility of
A. darlingi to P. vivax infection as well as studies of this
vector’s genome and population genetics have been also
studied.13,15,16 Several factors have been identiﬁed that aﬀect
the infection of mosquitoes by malaria parasites. These include
environmental factors, such as temperature and humidity,17
genetic factors, such as evasion of mosquito immunity by the
parasite,18 and host-related factors such as cytokines.19 The
production and development of Plasmodium sporozoites in
A. darlingi species has been understudied. Here, we describe
strategies and methods (from blood processing to insectary
management) that facilitate and improve the production of
infective P. vivax sporozoites in a well-established colony of
A. darlingi.
■ RESULTS AND DISCUSSION
To validate the vector competence of the Anopheles darlingi
colony, paired-infections with the same P. vivax blood donor
were performed with lab-reared mosquitoes (from F1 to F12)
compared to F1 from wild A. darlingi by SMFA. No signiﬁcant
diﬀerences were detected between the control group (F1 from
wild A. darlingi females) and mosquitoes from the colony in any
experiment regarding infection intensity (geometric mean from
the wild 13 (range of 1−93) and in the colony 10 (range of 1−
133); Wilcoxon matched-pairs rank test p = 0.3804) or in
sporozoite yield per mosquito from the wild (geometric mean
1080 (range of 170−7380) and from the colony 879 (range of
150−6300); Wilcoxon matched-pairs rank test p = 0.3203).
From 2012 to 2016, a total of 219 P. vivax infections in
A. darlingi were performed, with a mean age (years) of blood
donors of 33.38 (range of 18−55). Parasitemia varied among
donors: asexual parasitemia (2 to 112 344 trophozoites per μL,
mean 6260 ± 677.2) and gametocytemia (18 to 11 820
gametocytes per μL, mean of 1016 ± 93). In ten experiments,
oocyst numbers were not recorded because of logistical issues.
Eight infections failed to produce oocysts in the mosquito
midgut (8/209), and then, over 96% of the assays infected
mosquitoes. About 60 000 female mosquitoes were employed
in the SMFAs of which more than 52 000 were dissected. The
infection prevalence (batches where at least one mosquito
presented oocysts in the midgut) among the positive infections
(n = 201) was quite high 76 ± 1.8 (±SE), range of 10−100.
The geometric mean number of oocysts observed per mosquito
infection varied from 1 to 396. Following,20 Plasmodium vivax
donors could be identiﬁed as high (n = 171) and low (n = 24)
transmitters, depending on whether geometric mean of oocyst
per midgut was ≥1 and infection prevalence was ≥30%.
To evaluate when sporozoites appeared in salivary glands,
independent time-series dissections (n = 16) (from diﬀerent
P. vivax donors) were performed with at least 20 mosquitoes
dissected per infection from day 9 pi to day 18 pi. Despite
variability among infections, sporozoite numbers peaked on
days 14 and 15 pi (Figure 1), thereafter declining in salivary
gland sporozoites.
Correlation of P. vivax gametocytemia with density of
infection (mean oocysts per mosquito midgut) and prevalence
of infection was analyzed with data from 202 SMFAs.
Prevalence and intensity of infection in the mosquitoes were
signiﬁcantly correlated with total gametocytemia (R = 0.6465, p
< 0.0001; R = 0.5534, p < 0.0001, respectively) (Figures 2A,B
and 3).
Salivary gland dissections were performed on 147 SMFA-fed
mosquito batches; of these, 7 failed to yield sporozoites. Mean
sporozoite yield per mosquito was 6539 (range of 57−98 600),
and intensity of infection was correlated with sporozoite
production (R = 0.5603; p < 0.0001).
The experiments reported here conﬁrm the susceptibility of
free-mating A. darlingi to P. vivax under long-term colony
conditions, as evidenced by the successful experimental SMFAs
in 201 successful mosquito infections using P. vivax samples
collected from 2012 to 2016. Over this time period, more than
157 × 106 P. vivax sporozoites were obtained, with variability in
the number of sporozoites per mosquito, reaching up to
∼98 000 sporozoites per mosquito. Overall, these data indicate
that colonized A. darlingi mosquitoes remain susceptible to
P. vivax infection; over 95% of the samples (201/210) produce
gametocytes, and 95% (140/147) of the salivary gland dissected
contained sporozoites.
The substantial variation in oocyst intensities among assays
may be explained by several factors that have been
hypothesized to inﬂuence transmission, such as gametocyte
density,21,22 maturity and sex-ratio of the sexual parasites,23,24
and host−mosquito immune factors, among others. We were
not able to identify signiﬁcant diﬀerences in gametocytemia
among transmitting and nontransmitting donors. This study
was not designed to test any of these other parameters, but
future work will focus on how these factors correlate with
P. vivax transmission. Overall, there was a correlation between
Figure 1. Timeline to estimate the number of sporozoites/mosquito
after P. vivax infection. Salivary gland dissection started from day 9 pi
until day 18 pi (n = 800 mosquitoes). Error bars represent the
standard error of the mean of 16 independent experiments.
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gametocytemia and the number of sporozoites in A. darlingi
salivary glands, as other studies in the region have
demonstrated.13,22,25
Serum replacement was performed in 14 independent
experiments with a signiﬁcant increase between samples
without (geometric mean = 13.51, oocyst range of 1−187)
Figure 2. Correlation analysis between Plasmodium vivax parasitemia (/μL blood) and (A, B) number of oocysts per midgut and (C) sporozoites in
salivary glands in A. darlingi. Spearman’s rank correlation coeﬃcient and bivariate density contours. Total number of infections included in the
analysis for oocysts/midgut (n) = 201; total number of infections included for sporozoites analysis (n) = 147.
Figure 3. Proportion of infections according to (A) gametocytemia vs oocyst density, (B) gametocytemia vs infection prevalence, and (C)
sporozoite density vs oocyst density. The bar widths are proportional to the number of cases within each category. Total number of infections
included in the analysis for oocysts/midgut (n) = 201; total number of infections included for sporozoites analysis (n) = 147.
Figure 4. Violin plots showing the distribution of the data where the width of each polygon illustrates the relative frequency of (A) P. vivax oocysts
with diﬀerent anticoagulants in blood donors. EDTA, citrate, and heparin were tested in ten independent assays with a total of 540 dissected
mosquitoes. Heparin was signiﬁcantly diﬀerent against the other two treatments in the number of oocysts production. (B) P. vivax infectivity oocysts
and antibiotic exposure. PS/blood: penicillin and streptomycin mixed with blood; PS/sugar: penicillin and streptomycin mixed with the sugar
solution; control: control group. No signiﬁcant diﬀerences were detected.
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and with (geometric mean = 47.82, oocyst range of 1−324)
serum replacement. The eﬀect of EDTA, heparin, and citrate
anticoagulants on mosquito infectivity was assessed by
experiments with ten diﬀerent P. vivax donors (blood from
the same volunteer was oﬀered to diﬀerent batches of
mosquitoes for each of the treatments) and at least 18
dissected midguts per treatment. A total of 540 mosquitoes
were dissected on day 8 pi, and oocysts were enumerated.
Using heparin to anticoagulated P. vivax, donor blood was
associated with signiﬁcantly higher oocyst numbers (geometric
mean of 74.9; range of 4−322) than use of EDTA (55.30; range
of 2−248; nonparametric Mann−Whitney’s test, p = 0.021) or
citrate (34.89; range of 4−238; p = 0.016)) (Figure 4A).
To assess whether the use of antibacterials aﬀected infection
outcomes, 16 experiments using PS were performed in which a
total of 600 mosquitoes were fed. Ten mosquitoes for each of
the treatments, PS mixed with blood (PS/blood), PS mixed
with the sugar solution (PS/sugar) and a control group
(without PS), were dissected at day 8 pi (n = 450). Pairwise
comparisons of feeding conditions did not indicate a signiﬁcant
increase in the intensity of infection (oocysts/per mosquito
midgut) (geometric means of 49.03 (range of 145−301) for
PS/sugar, 50.72 (range of 68−321) for PS/blood, and 53.32
(range of 188−322) for the control group (Figure 4B)).
Mosquito survival was assessed in experiments with addition
of PS to the routine 10% sugar diet in 15 feeding experiments
(n = 7210 mosquitoes), using as a control group mosquitoes
feeding only on 10% sugar (n = 5520). Mortality was evaluated
in both groups daily from day 1 (after emergence) to day 14.
Overall, there was a signiﬁcant reduction of mortality, from
48% to 26%, when PS was used, and the hazard ratio for death
in the PS/sugar treatment was HR = 2.28 (SE ± 0.082; p <
0.0001) and in the control group HR = 2.70 (SE ± 0.114; p <
0.0001) (Figure 5).While addition of PS to sugar maintenance
did not have an eﬀect on oocyst production, this treatment
enhances survival of fed A. darlingi mosquitoes.
The eﬀect of methyl-paraben on mosquito survival was tested
in 14 replicates with a total of 450 female mosquitoes in each
group. Methyl-paraben had no measurable eﬀect on mosquito
survival or on oocyst production.
The inclusion of ATP in the SMFA blood meal to stimulate
feeding in A. darlingi was evaluated performing three replicates
with a total of 840 female mosquitoes. The proportion of fed
mosquitoes was similar to no statistical diﬀerences between the
concentrations: 86 ± 2 (1 mM), 81 ± 8 (0.1 mM), and 79 ± 2
(0 mM, control). In the presence of exogenous ATP, there was
no diﬀerence in infection intensity (n = 280): 85.69 (oocyst
range of 1−128) (1 mM ATP), 80.01 (oocyst range of 1−144)
(0.1 mM ATP), and 78.44 (oocyst range of 1−135) (control, 0
mM ATP).
Diﬀerent approaches were compared to optimize sporozoite
production in the mosquitoes. First, we tested diﬀerent
compounds that are known to inﬂuence the parasite develop-
ment in the mosquito, such as PS or anticoagulants. Second,
extending mosquito lifespan increases the number of
mosquitoes able to be dissected on days 14 and 15 and,
therefore, yields more sporozoites for liver cell infections.
Finally, the eﬀect of ATP, a purported mosquito feeding
stimulant, was also investigated regarding mosquito feeding
intensity, but no eﬀect was seen. Among all the strategies
performed, the replacement of serum, use of heparin as
anticoagulant to process donor blood, and the inclusion of PS
in the sugar solution were associated with improvement in the
salivary gland sporozoite yield.
Here, we demonstrate continuous production of Plasmodium
vivax sporozoites in the malaria-endemic region of the Peruvian
Amazon, where infected subjects and a sustained colony of the
major malaria vector Anopheles darlingi are both present.
Enhancement of sporozoite yield was aﬀected through various
Figure 5. Kaplan−Meier survival curves of Anopheles darlingi under PS treatments. Mortality was recorded in adult mosquitoes from day 1 to 15. PS/
B: Pen/Strep in blood meal; PS/S: Pen/Strep in sugar; C: control, blood meal without Pen/Strep.
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technical measures. Using heparin to collect and process donor
blood and penicillin−streptomycin supplementation of main-
tenance sugar meals during routine insectary maintenance
enhanced oocyst and sporozoite yields as well as mosquito
survival. The use of heparin is consistent with previously
reported results for the development of P. vivax in
A. albimanus.26 Most importantly, we were able to obtain
high P. vivax sporozoite yields, sometimes as many as 98 000
sporozoites per mosquito per salivary gland dissection.
Experiments determining P. vivax sporozoite viability and
capacity to invade hepatocytes as well as testing antimalarial
drugs in hepatic stages are detailed in the accompanying article
(Orjuela-Sanchez et al.44). The identiﬁcation of molecular
correlates to detect gametocyte fertility in P. vivax and
sporozoite yield would beneﬁt these experiments in terms of
reproducibility and robustness.
The data presented here demonstrate a robust and enhanced
P. vivax sporozoite yield in the main malaria vector in the
Americas, Anopheles darlingi. This work will lead to new drug
discovery and vaccine development eﬀorts and to new
understandings of the biology and ways to intervene against
liver stage parasites, including hypnozoites.1,27
■ METHODS
Plasmodium vivax Donors. To supply infectious game-
tocytes, donor subjects were enrolled in the city of Iquitos,
Department of Loreto, Peru, where P. vivax accounts for ∼80%
of malaria cases, with the remaining ∼20% being due to
P. falciparum. In 2016, this Department reported ∼54 000
malaria cases,28 representing more than 95% of all malaria cases
nationwide. From 2012 to 2016, subjects, ≥18 years old,
microscopically diagnosed with P. vivax malaria were invited to
participate in the study with written informed consent. All
participation was voluntary, and the decision to participate had
no eﬀect on treatment, which is provided free of charge by the
Peruvian government according to the Peruvian Ministry of
Health guidelines. Thick and thin blood smears were prepared
from whole blood from each individual volunteer, stained with
10% Giemsa, and examined by experienced microscopists to
exclude patient mixed infections with P. falciparum. Parasites
and mature gametocyte stage densities were estimated by
counting the number of parasites per 500 white blood cells
under light microscopy with a 100× immersion oil lens.29
Approximately 10 mL of blood was collected by venipuncture
and placed in a constant 37 °C water bath to arrest
gametogenesis. These cultures were then used within 1 h of
collection for standard membrane blood feeding (SMFA).30
Mosquito Infections. Anopheles darlingi mosquitoes from a
laboratory-established colony were laboratory reared as
previously described.13 Three-day old A. darlingi female
mosquitoes, deprived of sucrose overnight, were placed in
small paper cups (number of specimens depended on the
experiment) and used for each assay. Between 0.5 and 1 mL of
heparinized blood from each volunteer was added to a 1.5 cm
diameter glass membrane feeder ﬁtted with a paraﬁlm
membrane and maintained at 37 °C during the whole
experiment to prevent gametogenesis. Mosquitoes were
allowed to feed for 30 min in the dark; then, unfed mosquitoes
were removed, and fed mosquitoes were maintained in the
insectary at 27 ± 1 °C and 70−80% relative humidity and
supplied with sugar water ad libitum.
Oocyst and Sporozoite Counts. Midguts were dissected,
stained with 1% mercurochrome, and counted with a phase-
contrast microscope (40×) on days 7 and 8 postfeeding to
estimate oocyst prevalence (percentage of mosquitoes infected)
and infection intensity (number of oocysts/mosquito). It is
known that sporozoite density in mosquito salivary glands
accumulates over time.31 To determine the optimum time for
mosquito dissections to maximize number of P. vivax
sporozoites per mosquito, salivary gland dissections of
individual specimens were performed, from day 9 postinfection
(pi) up to day 18 pi. Mosquitoes were anesthetized at 4 °C,
placed in a Petri dish with 70% ethanol, and then washed twice
with DMEM sterile medium (Life Technologies #11965118).
Salivary glands were dissected under a stereomicroscope,
homogenized together (mosquitoes from the same batch) in
a glass tissue grinder, ﬁltered through a nylon cell strainer (40
μm pore size), and then centrifuged at 12 000 rpm for 3 min.
Sporozoite numbers were counted using a Neubauer chamber
hemocytometer using a phase-contrast microscope (40×).
Strategies To Increase Oocysts and Sporozoites
Production/Yield in A. darlingi. To identify factors that
may improve the yield of infective sporozoites, several
experiments were designed.
Serum Replacement of Blood Samples. To assess the eﬀect
of plasma on mosquito infection, each blood sample was
prepared with and without serum replacement. Plasma was
removed from P. vivax-infected packed red cells after
centrifugation at 500g for 5 min at 37 °C and replaced with
an equal volume of heat-inactivated (30 min at 56 °C) O+
plasma (the most common regional blood type) from donors
from Lima, Peru, a nonmalaria endemic area, who reported no
travel history to malaria-endemic areas.32 Mosquitoes were
separated in two experimental groups (50 mosquitoes per
group); one group was oﬀered whole blood and the other,
blood with inactivated-blood-serum replacement via MFAs.
Eﬀect of Anticoagulants in P. vivax Oocysts Production.
We posited that certain anticoagulants used in blood collection
might interfere with parasite viability, exﬂagellation, and
fertilization within the mosquito midgut, hence aﬀecting oocyst
production. Several studies have addressed this issue by
studying the parasite−mosquito model pairs P. falciparum−
A. stephensi33 and P. vivax−A. albimanus.26 To investigate the
potential eﬀect on P. vivax development in A. darlingi
mosquitoes, three common anticoagulants were tested:
EDTA, citrate-phosphate-dextrose, and heparin. Each blood
sample was collected and aliquoted into Vacutainer tubes
(Becton Dickinson, Franklin Lakes, NJ) with 6 mL of EDTA,
10 mL of heparin, or 6 mL of citrate and maintained in a 37 °C
water bath until membrane feeding to mosquitoes. Then, blood
was oﬀered simultaneously to batches of 50 A. darlingi
mosquitoes in 16 independent experiments. Midgut dissections
were performed on days 7 and 8 postinfection, and mean
oocyst counts and prevalence of infection were enumerated
using light microscopy.
Eﬀect of Antibiotics on P. vivax Development in
A. darlingi. Alterations on mosquito midgut microbiota have
been demonstrated to modify parasite infectivity to vectors.
Speciﬁcally, feeding P. falciparum to A. gambiae in the presence
of antibiotics added to sucrose solution increases oocyst
counts.34,35 A recent study showed that penicillin and
streptomycin (PS) added to donor blood increases mosquito
susceptibility to P. falciparum infection as well as enhances
mosquito survival rate and fecundity.36 To test the eﬀect of PS
on P. vivax oocyst development in A. darlingi, two diﬀerent
strategies were followed: (i) P. vivax-infected blood meal was
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supplemented with PS (Life Technologies #15070063) and
oﬀered to the mosquitoes through SMFA. In this experiment,
20 microliters of a cocktail containing 1000 μg/mL streptomy-
cin plus 1000 U/mL penicillin was added to 1 mL of blood.36
Control blood was supplemented with the same volume of
water with added PS. (ii) To supplement the sugar solution
where adult mosquitoes were fed with PS (1%), each P. vivax
infected blood sample was aliquoted following the above
procedures and then was oﬀered to batches of 50 mosquitoes
following three combinations: blood + PS and then 10% sugar;
blood alone; and then 10% sugar with PS. In addition to oocyst
production (midgut dissected on day 8 pi), the eﬀect of PS on
mosquito survival was evaluated on mosquitoes fed 10% sugar
supplemented with PS, starting at the time of emergence (days
1 to 14).
Use of Methyl-Paraben To Increase Mosquito Survival.
Methyl-paraben is an antifungal and antimicrobial routinely
used in sugar supplements in mosquito-rearing insectaries. In
A. gambiae, the addition of methyl-paraben to the mosquito
sugar maintenance meal has been demonstrated to increase
mosquitoes survival and infection rates (tested with P. cynomolgi
B).37 Here, we assessed the eﬀect of methyl-paraben on the
survival rate of A. darlingi and infection with P. vivax. Batches of
25 mosquitoes were fed aliquots from the same blood donor,
and then, diﬀerent treatments were evaluated in three
independent experiments (with three replicates per treatment):
(i) supplemented postinfection with methyl-paraben (SIGMA
#47889) + 10% sugar; (ii) supplemented only with 10% sugar;
(iii) 10% sugar + blood feeding.
Eﬀect of ATP on P. vivax Infection of A. darlingi.
Adenosine 5′-triphosphate (ATP) has been shown to stimulate
feeding in some mosquito species, such as Aedes aegypti, due to
the sensitivity of mosquito mouth parts (labral sensilla) to
ATP.38,39 To test whether adding ATP to a blood meal
increases the mosquito blood intake of blood and ampliﬁes
P. vivax burden in mosquitos, blood samples were aliquoted
and ATP (SIGMA #A3377) was added at concentrations of 0,
0.1, and 1 mM; the samples were oﬀered to diﬀerent batches of
mosquitoes in three independent experiments (n = 30
mosquitos per batch). The percentage of fed females after
SMFA as well as oocysts production was recorded.
Statistical Analysis. Prism 6 (GraphPad Software, San
Diego, USA) was used to perform summary statistics of
infection prevalence and density and number of sporozoites.
Results are presented as geometric means of original values for
each batch of mosquitoes. Sporozoite production for each
infection was determined from homogenized mosquitoes from
independent batches, and then, the yield was adjusted to the
number of mosquitoes dissected.40
Statistical analyses were conducted in R v.3.4.3 (R Develop-
ment Core Ream, R Foundation for Statistical Computing,
Australia). Spearman’s rho was calculated to evaluated
correlations between continuous skewed data (i.e., oocyst
density, oocyst prevalence, gametocytemia, and sporozoite
yield) with a signiﬁcance level of 0.05. For visualization
purposes, skewed data were categorized as follows: oocyst
density (breaks = 0, 5, 50, 100, 200, >200); oocyst prevalence
(0, 50, 75, 90, >90); gametocytemia (0, 250, 500, 750, 1000,
2000, >2000); sporozoite yield (0, 500, 1000, 3000,
>3000).41,42
Violin plots with probability quantiles (ggplot2 package) were
performed to visualize the density of the data in the use of
antibiotic and anticoagulants. Mann-Whitney’s U test was used
to assess statistical diﬀerences between treatments. The Kaplan-
Meier survival curve was used to present survival of mosquitoes
exposed to antibiotic vs control group during a 15 day follow-
up, and the mortality risk was evaluated with a mixed-eﬀects
Cox proportional hazard model (Hazard Ratio: HR).43 The
clustering of mosquitoes fed with the same blood donor was
modeled as a random eﬀect.
Ethics Statements. This study is part of the Amazonian-
ICEMR and was approved by the Ethics Review Board of the
Regional Health Direction of Loreto, Universidad Peruana
Cayetano Heredia in Lima (R-157-13-14), and the Human
Subjects Protection Program of the University of California,
San Diego, USA (approval number 120652). Written informed
consent was obtained from all study participants prior to
subject enrollment and blood sampling.
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